ALK and cancer: In the experimental arm, only 15 patients experienced disease recurrence, and subsequent treatments were determined by the investigator; subsequent treatments included ALK-TKI for 7 patients (alectinib or brigatinib), chemotherapy for 6 patients, immunotherapy for one patient and other anti-cancer therapy for one patient.